Healthcare

Addiction Biotech Cannabis Genetics Healthcare Medical Devices Pharmaceutical Science Veterinary
News Release Digital Asset Direct

ImmuPharma CEO Tim McCarthy discusses financial stability and promising drug developments

ImmuPharma PLC

ImmuPharma PLC (AIM:IMM) chief executive Tim McCarthy provides an extensive update during an interview with Proactive's Stephen Gunnion, focusing on the financial, business, and portfolio developments of the company. McCarthy clarified that the company is in a strong financial position, dismissing rumours of needing a highly dilutive fundraising. He emphasized that ImmuPharma has sufficient funding for its needs, supported by a business model reliant on developing drugs to a stage attractive to larger pharmaceutical companies for further development and market introduction. This strategy, according to McCarthy, is expected to generate non-dilutive upfront payments and royalties from licensing agreements, particularly for their P140 platform focused on autoimmune diseases like lupus and CIDP (Chronic Idiopathic Demyelinating Polyneuropathy). McCarthy detailed progress on the lupus program, including changes to their clinical study approach and discussions with the FDA, highlighting the uniqueness of their molecule's mechanism of action. This uniqueness, McCarthy pointed out, has garnered interest from big pharma, distinguishing their lupus treatment from others that failed due to efficacy or side effects issues. Moreover, he announced advancements in the CIDP program and the company's intention to achieve orphan drug designation for it, promising significant market potential despite its smaller patient population compared to lupus. The CEO also touched on an early-stage anti-infective program, underscoring the evolution of ImmuPharma's drug portfolio over the last two and a half years under his leadership. This transformation involved corporate restructuring, significant cost reductions, and strategic focus on developing a diversified drug portfolio. McCarthy concluded by affirming the company's position as substantially undervalued based on its developmental and financial assets, particularly highlighting a major interest in the oncology company Incanthera, which recently secured a substantial commercial deal with AS Watson. Contact Details Proactive UK Ltd +44 20 7989 0813 uk@proactiveinvestors.com

March 08, 2024 09:48 AM Eastern Standard Time

Video

Oncimmune's strategic pivot aims for robust growth in 2024

Oncimmune Holdings PLC

Oncimmune Holdings PLC (AIM:ONC) CEO Martin Gouldstone joins Proactive's Stephen Gunnion with highlights of the company's 2023 performance, which included its strategic decision to focus on its ImmunoINSIGHTS platform. A significant development was the sale of its early lung cancer detection business to US biotech company Freenome, generating substantial funds. This capital was utilised partly to reduce existing company debt and, importantly, established a five-year master service agreement (MSA) with Freenome, guaranteeing Oncimmune a minimum of £1.3 million in service revenues on a use-it-or-lose-it basis, with a two-year break clause. This deal not only provided immediate financial benefit but also assured a steady revenue stream for at least two years. Gouldstone emphasized the company's focus on its ImmunoINSIGHTS service platform, highlighting its commercial and scientific potential. Since his tenure began in August last year, Gouldstone said he has been dedicated to maximizing the platform's commercial impact and scientific capabilities. The strategic redirection towards new commercial areas and customer segments was marked by the announcement of a new strategy in October, followed by securing seven contracts in novel commercial domains, including repeat business with large pharmaceutical companies and new engagements in biotech. These contracts span discovery and adverse event prediction in immuno-oncology, reflecting the strategic diversification efforts. With the commercial team nearing completion, Oncimmune anticipates a tangible impact on revenues towards the end of 2024, with an aim to further expand the sales team in the US by FY25. Looking ahead to 2024, Oncimmune has projected a revenue target of £3 million, marking at least a 150% increase from the previous year and setting a record high for the company's operations in Germany. This ambitious forecast underscores the company's strategic refocus, relaunch, and consolidation efforts aimed at sustaining growth and delivering improved financial performance in the coming years. Contact Details Proactive UK Ltd +44 20 7989 0813 uk@proactiveinvestors.com

March 08, 2024 09:35 AM Eastern Standard Time

Video

Headline

Benzinga

By Meg Flippin, Benzinga When it comes to neurological diseases, epilepsy is among the most common worldwide. At last check, about 50 million people suffer from this chronic non-communicable disease, with close to 80% living in low to middle-income countries. The risk of premature death among epilepsy patients is as much as three times higher than non-suffers. There are treatments for the seizures experienced by patients – 28 FDA-approved drugs at last count – but they don’t work for everyone. About one-third require surgery. It is those patients and others suffering from neurological disorders that Minnesota-based NeuroOne Medical Technologies Corp.(NASDAQ: NMTC) is targeting with its medical technology. The company designs and manufactures high-definition, minimally invasive thin film electrodes which are used for intracranial monitoring. The electrodes are implanted inside the skull to record brain activity. That data helps surgeons better locate and remove the brain tissue causing seizures without impacting the rest of the brain. NeuroOne’s electrodes are intended to diagnose and treat several neurological conditions including epilepsy, Parkinson’s Disease and Essential Tremors. The company believes it has an edge over the current electrodes in application because they are thin, flexible and less bulky. Better Than The Original? NeuroOne’s Evo Cortical Electrode portfolio consists of various configurations of strips and grid electrodes, which are made with thin polyimide film — which, in a study by the Mayo Clinic, demonstrated reduced inflammation to the brain versus traditional silicone electrodes as the material is flexible, thin and weighs less. The electrodes are cleared by the FDA for recording, stimulation and monitoring of brain activity for less than 30 days. With the technology, doctors can identify the right foci zones to determine the best treatment for patients. The company says its technology provides new options for surgical placement and potentially smaller incisions, lower inflammation compared to the bulky electrodes on the market, and also enables the pairing of diagnosis and therapeutics in one offering unlike other competitive technologies. With proven placement accuracy and enhanced signal quality, physicians can capture the vital data they need to support more confident diagnoses, according to NeuroOne. NeuroOne is among a handful of medical technology companies that are taking novel approaches to treating brain diseases. Aneuvas Technologies Inc. (NASDAQ: ATITK) is one example. It's developing new technology to fill and heal aneurysms. Hong Kong-listed MicroPort NeuroTech Ltd. is another example, working on technology to help doctors overcome potential issues during hemorrhagic strokes. Meanwhile ORSIM develops a specialist flexible bronchoscope simulator to help train and support anesthesiologists. NeuroOne pegs its market opportunity at $100 million for diagnostic use. Other markets the company is looking to enter including ablation, drug delivery and spinal cord stimulation for back pain are already generating revenue in the billions of dollars. Future Applications On The Horizon The company recently received clearance from the FDA to use an sEEG electrode to record electrical activity in the brain for less than 30 days but also to ablate brain tissue in an effort to reduce or eliminate a patient’s seizure activity using the same device. This will hopefully reduce the number of surgeries and hospitalizations a patient has to experience. This system has the potential to ablate nervous tissue in other areas of the body. NeuroOne has already commented that they will pursue additional applications, starting with facial pain. In addition, the company has commented that they are developing a drug delivery electrode that can monitor the electrical activity of the brain after delivery of the drug or gene therapy. This technology could also be helpful for pharmaceutical and biotech companies in helping identify in the early phases of development if the therapy shows efficacy. This could save the company millions of dollars in development and clinical study costs earlier in the development process. In addition, NeuroOne is also expanding its efforts into spinal cord stimulation for chronic back pain, last year announcing it successfully completed an animal implant of its novel thin film paddle leads for spinal cord stimulation. The devices are intended for the treatment of patients with chronic back pain due to multiple failed back surgery syndrome and intractable low back and leg pain. NeuroOne reports that results demonstrated the feasibility of the placement of a thin film paddle lead intended to treat chronic back pain due to multiple failed back surgeries. The company said more testing would be completed to optimize the design and placement. The company is also developing a percutaneous (through a needle) paddle lead placement system which would eliminate the need for an incision in the patient's back. The preliminary benchtop testing for this percutaneous approach has also been successfully completed. In January, NeuroOne presented a poster on pre-clinical experience with thin-film paddle leads at the North American Neuromodulation Society (NANS). Millions of people suffer from epilepsy, Parkinson’s Disease, Essential Tremors and other neurological disorders, yet the treatments today largely fall short. NeuroOne is committed to changing that with its minimally invasive approach. It hopes its innovations will not only transform the treatment of brain diseases but also enhance patient outcomes, reduce procedural invasiveness and streamline diagnostic and therapeutic processes for patients around the globe. Featured photo by Natasha Connell on Unsplash. Benzinga is a leading financial media and data provider, known for delivering accurate, timely, and actionable financial information to empower investors and traders. This post contains sponsored content. This content is for informational purposes only and is not intended to be investing advice. Contact Details Benzinga +1 877-440-9464 info@benzinga.com Company Website http://www.benzinga.com

March 08, 2024 08:30 AM Eastern Standard Time

Image

Syra Health (NASDAQ: SYRA) Wins $650,000 Healthcare Quality Improvement Contract

Syra Health

By Jeremy Golden, Benzinga Syra Health’s (NASDAQ: SYRA) new deal to collect data and acquire information related to Healthcare Effectiveness Data and Information Set (HEDIS®) will further the Carmel, Indiana-based company’s goal of providing innovative services and technology solutions in the healthcare sector. Developed and maintained by the National Committee for Quality Assurance (NCQA), HEDIS is a standardized population health management tool that employers can use to understand employee health and measure the quality of care their population receives. HEDIS plays a critical role in healthcare quality measurement and improvement initiatives as the most widely used performance improvement tool in healthcare. As per the agreement, Syra Health will provide HEDIS outreach and support services essential for fostering positive health outcomes and reducing costs. Syra Health, whose products and services are centered on prevention, improved access and affordable care, will leverage its team of population health experts to collect data and acquire information from the Indiana population, including Medicaid members, hospitals and physicians. "The need for robust data and analytics by healthcare decision-makers is continuing to expand,” said Dr. Deepika Vuppalanchi, CEO, Syra Health. “We are proud that we are being recognized for our strong team of health experts.” “We remain steadfast in pursuing and securing important contracts for our services and products,” added Sandeep Allam, Executive Chairman and President, Syra Health. “Our contract pipeline is growing, and we look forward to sharing more contracts as they are fully executed.” Featured photo by Matheus Ferrero on Unsplash. Syra Health is a healthcare technology company addressing some of healthcare's most significant challenges in areas such as behavioral and mental health, digital health, and population health, by providing innovative services and technology solutions. Syra Health’s products and services are centered on prevention, improved access, and affordable care. Syra Health supplies its solutions to payers, providers, life sciences organizations, academic institutions, and government. For more information, please visit www.syrahealth.com. Statements in this press release about future expectations, plans, and prospects, as well as any other statements regarding matters that are not historical facts, may constitute "forward-looking statements." These statements include, but are not limited to, statements relating to the expected use of proceeds, the Company’s operations and business strategy and the Company’s expected financial results. The words "anticipate," "believe," "continue," "could," "estimate," "expect," "intend," "may," "plan," "potential," "predict," "project," "should," "target," "will," "would" and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. The forward-looking statements contained in this press release are based on management's current expectations and are subject to substantial risks, uncertainty and changes in circumstances. Investors should read the risk factors set forth in our registration statement on Form S-1 and other periodic reports filed with the Securities and Exchange Commission. Any forward-looking statements contained in this press release speak only as of the date hereof, and, except as required by federal securities laws, the Company specifically disclaims any obligation to update any forward-looking statements, whether as a result of new information, future events, or otherwise. This post contains sponsored content. This content is for informational purposes only and is not intended to be investing advice. Contact Details Christine Drury +1 463-345-8950 Christined@syrahealth.com Company Website https://www.syrahealth.com/

March 08, 2024 08:25 AM Eastern Standard Time

Image

Immunic to reveal promising MS treatment data in two poster presentations at ACTRIMS Forum 2024

Immunic Inc

Immunic Inc CEO Dr Daniel Vitt joins Proactive's Stephen Gunnion with details of data from the Phase 2 CALLIPER and CALVID-1 trials of vidofludimus calcium the company will present at the Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS) Forum 2024 in West Palm Beach, Florida, from today. Vitt highlighted the significant potential of the drug in treating multiple sclerosis (MS), particularly in relation to Epstein-Barr Virus (EBV) reactivation. The CALLIPER study focuses on the effects of 45 milligrams of vidofludimus calcium in patients with progressive MS, emphasising the importance of progression independent of relapse activity. October's interim biomarker data, specifically neurofilament light chain (NFL), which is related to neuronal death, was mentioned as a key aspect of the first poster. This data aims to correlate NFL reduction with the likelihood of future disability outcomes in progressive MS patients. The overlap between the CALLIPER study and the Phase 2 CALVID-1 trial, outlined in the second poster, explores the role of EBV reactivation in MS and fatigue symptoms. Vidofludimus calcium's potential to prevent EBV reactivation and reduce fatigue in MS patients is a significant finding, with implications for post-COVID syndrome as well. The CALVID-1 study also examined Vidofludimus calcium's effects on fatigue in patients treated for SARS-CoV-2, revealing a positive impact. Presenting at the ACTRIMS Forum 2024, an important scientific conference for MS research, underscores the relevance and potential impact of Immunic Inc's findings in the MS and broader medical communities. Contact Details Proactive North America +1 604-688-8158 NA-editorial@proactiveinvestors.com

March 08, 2024 06:53 AM Eastern Standard Time

Video

Redx Pharma achieves milestone with dosing of first participant in Phase 1 clinical trial for RXC008

Redx Pharma PLC

Redx Pharma PLC (AIM:REDX) CEO Lisa Anson discusses the enrollment of the first participant in its RXC008 Phase 1 clinical trial in an interview with Proactive's Stephen Gunnion. RXC008 is a 'first-in-class' ROCK inhibitor, designed to be gut-restricted, targeting fibrostenotic Crohn's disease. This oral molecule inhibits ROCK1 and ROCK2, aiming to avoid systemic side effects like hypertension, and providing targeted action in the gut. This development marks a significant step from laboratory to patient-focused clinical development. Anson highlighted the unmet need for Crohn's disease treatment, particularly for patients with fibrostenotic complications, where currently no drug treatments are available, leaving surgery as the only option. The next steps for the RXC008 programme include escalating doses in healthy volunteers, with plans to move into patient trials towards the end of the year. Additionally, Anson mentioned Redx Pharma's broader portfolio, noting that RXC008 is the sixth molecule from Redx to enter clinical trials, showcasing the company's drug discovery prowess. Other key developments include the Phase 2 trials of RXC007 for lung fibrosis and RXC004 for cancer, both expected to report data this year. Contact Details Proactive UK Ltd +44 20 7989 0813 uk@proactiveinvestors.com

March 08, 2024 05:46 AM Eastern Standard Time

Video

Innoveren Scientific's (OTCMKTS: IVRN) 510(k) Submission Sparks A New Hope For Patients Living With Chronic Non-Healing Wounds

Benzinga

By Jeremy Golden, Benzinga IVRN has completed a 510(k) submission for its SkinDisc TM Lite and SkinDisc TM regenerative medicine technology. The company says that what differentiates this technology from other regenerative products is the fact that it only requires one application to achieve healing in four to nine weeks and comes packaged as a disposable kit. An aging U.S. population with increasingly complex medical diagnoses has doctors and clinicians under pressure to diagnose and treat patients while restoring their quality of life. With the goal of doing just that, a life science and biotech incubator company is advancing a wound-healing product. Focused on advancing new technologies in areas of unmet need across multiple indications, Innoveren Scientific Inc. This is a significant advancement when compared to current treatment approaches that require weekly applications and can take 12-20 weeks to heal. Generally, people have to apply treatment products every three days before they see any impact. With SkinDisc, only one application is needed. SkinDisc TM was acquired by Innoveren Scientific in December of 2022. A breakthrough stem cell therapy technology, SkinDisc TM has positioned the company to combat the rising prevalence of acute, chronic and surgical wounds with an effective and affordable treatment. As outlined in its submission, SkinDisc TM combines stem cells from the patient and several other molecular components to stimulate tissue regeneration, which results in rapid growth of the host tissue. To best serve those who can benefit from this proprietary technology, Innoveren Scientific plans to work with surgeons, podiatrists and physicians to treat patients with severe trauma-based wounds and non-healing chronic wounds, which affected nearly 16.3% of Medicare beneficiaries in 2019, according to a recent study by the University of Pittsburgh Medical Center. Those numbers are only expected to continue on an upward trajectory. Innoveren's recent submission to the U.S. Food & Drug Administration (FDA) is primarily focused on chronic non-healing wounds and burns, an area of medicine where current treatment options have stagnated. With patented or under-patented components, SkinDisc TM has treated over 500 patients to date. Innoveren reports that early clinical outcomes of those who used SkinDisc TM demonstrated significant results relative to current treatment options in wound healing and limb salvage. Innoveren Scientific expects to receive a response from the FDA by mid-May 2024 for both SkinDisc TM and SkinDisc TM Lite. This 510(k) submission is one of three the company has in its pipeline utilizing the body's own cells to achieve successful recovery of the patient. In the coming months, Innoveren plans to submit an application to the FDA for its SkinDisc TM Ultra technology, an iteration that incorporates Bone Marrow Aspirate (BMA) and would only be available for use in operating rooms and limb salvage procedures; specifically in cases of severe trauma, infections or diabetic foot ulcers. In addition to SkinDisc TM, the company also has BreatheEasy, a 510(k) De Novo pathway medical device that helps patients struggling with chronic obstructive pulmonary disease (COPD), as well as other closely related diseases such as chronic bronchitis and emphysema. Featured photo by megaflopp on Shutterstock. Benzinga is a leading financial media and data provider, known for delivering accurate, timely, and actionable financial information to empower investors and traders. This post contains sponsored content. This content is for informational purposes only and is not intended to be investing advice. Contact Details Benzinga +1 877-440-9464 info@benzinga.com Company Website http://www.benzinga.com

March 07, 2024 08:30 AM Eastern Standard Time

Image

How Healthcare Triangle (NASDAQ: HCTI) Is Helping Drive AI Adoption In Healthcare

Benzinga

By Faith Ashmore, Benzinga AI is rapidly transforming the healthcare industry, with an increasing demand and need for its implementation. One of the key drivers behind this rising demand is the ability of AI algorithms to analyze large volumes of patient data, quickly identifying patterns and making accurate predictions about diseases, treatment plans and outcomes. The implementation of AI in healthcare has the potential to revolutionize the industry, improving patient outcomes, reducing costs, and ultimately, saving lives. Healthcare is at a pivot point where AI-driven solutions are becoming more and more common. Companies that were quick to adapt or are currently taking steps to integrate AI are likely to be much further ahead than companies that are resistant to the technology. However, not every healthcare company has the capacity to seamlessly integrate AI technology into its systems. That's where organizations like Healthcare Triangle Inc. (NASDAQ: HCTI) come into play. Healthcare Triangle works collaboratively with various healthcare entities, such as hospitals, health systems, payers and pharma/life sciences organizations. The company focuses on developing specific AI applications that address clinical needs across a wide range of medical specialties. Whether it's using predictive analytics in oncology or precision medicine in cardiology, its goal is to revolutionize patient care in every aspect. This tailored approach represents a shift towards a healthcare ecosystem where AI-driven insights play an integral role in clinical decision-making, ensuring that healthcare providers remain at the forefront of an ever-evolving industry. “As we navigate towards a future where AI integration becomes synonymous with healthcare excellence, our solutions and services will represent a crucial pivot point,” shared Anand Kumar, Chief Revenue Officer at Healthcare Triangle. “We are setting a new standard for patient care, leveraging AI and LLMs to deliver personalized, predictive, and effective healthcare solutions with our expertise in providing privacy and security adhering to our HITRUST certification and HIPAA compliance. The future is unequivocal in its demand for AI enablement, and with Healthcare Triangle, healthcare providers are equipped to meet this challenge head-on.” The market for AI in healthcare is forecasted to experience growth; in 2023, the global AI in healthcare market was valued at $22.45 billion and it is projected to reach $53.0 billion by 2024. This upward trend reflects the market's progression from $11.06 billion in 2021 to approximately $15.1 billion by the end of 2022. What's particularly noteworthy is the projected overall market value of $187.95 billion by 2030. AI has the potential to revolutionize healthcare among other sectors, and companies like Healthcare Triangle are helping shape the future. Featured photo by Steve Johnson on Unsplash Benzinga is a leading financial media and data provider, known for delivering accurate, timely, and actionable financial information to empower investors and traders. This post contains sponsored content. This content is for informational purposes only and not intended to be investing advice. Contact Details Benzinga +1 877-440-9464 info@benzinga.com Company Website http://www.benzinga.com

March 07, 2024 08:25 AM Eastern Standard Time

Image

Could This Common Virus Unlock New Cancer Treatments? Theriva Biologics Believes That Adenoviruses Could Be Instrumental In The Next Evolution Of Oncology

Benzinga

By Faith Ashmore, Benzinga In the world of medicine, sometimes the most unexpected biological material can become vital to treatments for deadly diseases. One example of this is adenoviruses, which are non-enveloped, double-stranded DNA viruses that belong to the Adenoviridae family. They have a wide range of serotypes, or strains, with more than 50 types known to infect humans. Adenoviruses can cause respiratory, gastrointestinal and ocular infections in humans. However, adenoviruses have attracted attention in recent years due to their potential use in gene therapy and vaccine development. Their ability to efficiently deliver genes into mammalian cells has made them valuable tools in medical research, and they’re being explored as potential treatments for certain genetic disorders. Theriva Biologics (NYSE American: TOVX) is a biotech company that is looking to use adenoviruses in its novel cancer treatment. Adenoviruses are a class of viruses with an established safety profile and are highly prevalent in the environment, making them ideal candidates for therapeutic use in the cancer field. Theriva Biologics' lead product candidate, VCN-01, is a uniquely modified human adenovirus type 5 that is designed for systemic delivery to treat different types of cancer. This systemic delivery approach means that it can target both the main tumor and the distant metastases, making it a promising therapeutic option for various advanced and difficult-to-treat cancers. One of the additional distinguishing features of the VCN-01 adenovirus is its ability to degrade the protective barrier around the tumor, referred to as the stroma or the matrix. To do this, it releases an enzyme called hyaluronidase, which is a unique feature not found in other viruses being developed as cancer therapies. The virus's high replication capacity allows more virus particles and more hyaluronidase to be produced in the tumor, thereby degrading the stroma and making the tumor more immunogenic and receptive to chemotherapy and immunotherapy. By killing tumor cells and breaking down the tumor protective barrier, the virus can also turn a cold tumor "hot" and further facilitate immune system activity. Theriva Biologics reports that phase 1 clinical trials of VCN-01 have shown promising results when administered alone or with chemotherapy or immunotherapy in several different indications, including pancreatic cancer, retinoblastoma, head and neck squamous cell carcinoma (HNSCC) and colorectal cancer (CRC). Theriva Biologics is currently advancing VCN-01 in a phase 2b clinical trial in combination with standard-of-care chemotherapy for first-line metastatic pancreatic cancer. The company says it is on track to complete enrollment of all participants in the VIRAGE Study by the first half of 2024, which would mark an important milestone in the candidate’s development. The company is considering an interim analysis of the data collected during the VIRAGE Study by the second half of 2024. This analysis will offer valuable insights into the effectiveness of VCN-01 and its potential as a treatment option for first-line metastatic pancreatic cancer. If the company can successfully harness the benefits of adenoviruses, it will present suffering patients around the globe with a novel solution to extend their lives. CG Oncology (NASDAQ: CGON), Calidi Biotherapeutics (AMEX: CLDI) and Candel Therapeutic s (NASDAQ: CADL) are companies also advancing different adenoviruses for cancer treatment. Featured photo by National Cancer Institute on Unsplash. Benzinga is a leading financial media and data provider, known for delivering accurate, timely, and actionable financial information to empower investors and traders. This post contains sponsored content. This content is for informational purposes only and is not intended to be investing advice. Contact Details Benzinga +1 877-440-9464 info@benzinga.com Company Website http://www.benzinga.com

March 06, 2024 08:30 AM Eastern Standard Time

Image

1 ... 40 41 42 43 44 ... 250